Registro:

Referencias:

• Abdallah, H.M., Al-Abd, A.M., El-Dine, R.S., El-Halawani, A.M., P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review (2015) J. Adv. Res., 6, pp. 45-62
• Alghasham, A.A., Cucurbitacins – a promising target for cancer therapy (2013) Int. J. Health Sci., 7, pp. 77-89
• Ansari, J., Shackelford, R.E., El-Osta, H., Epigenetics in non-small cell lung cancer: from basics to therapeutics (2016) Transl. Lung Cancer Res., 5, pp. 155-171
• Aribi, A., Gery, S., Lee, D.H., Thoennissen, N.H., Thoennissen, G.B., Alvarez, R., Ho, Q., Koeffler, H.P., The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer (2013) Int. J. Cancer, 132, pp. 2730-2737
• Arumuggam, N., Bhowmick, N.A., Rupasinghe, H.V.P., A review: phytochemicals targeting JAK/STAT signaling and IDO expression in cancer (2015) Phytother. Res., 29, pp. 805-817
• Cai, Y., Fang, X., He, C., Li, P., Xiao, F., Wang, Y., Chen, M., Cucurbitacins: a systematic review of the phytochemistry and anticancer activity (2015) Am. J. Chin. Med., 43, pp. 1331-1350
• Callaghan, R., Luk, F., Bebawy, M., Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? (2014) Drug Metab. Dispos., 42, pp. 623-631
• Chen, J.C., Chiu, M.H., Nie, R.L., Cordell, G.A., Qiu, S.X., Cucurbitacins and cucurbitane glycosides: structures and biological activities (2005) Nat. Prod. Rep., 22, pp. 386-399
• Chen, X., Bao, J., Guo, J., Ding, Q., Lu, J., Huang, M., Wang, Y., Biological activities and potential molecular targets of cucurbitacins: a focus on cancer (2012) Anti-Cancer Drugs, 23, pp. 777-787
• Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., Wong, K.-K., Non-small cell lung cancers: a heterogeneous set of diseases (2014) Nat. Rev. Cancer, 14, pp. 535-546
• Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies (2006) Pharmacol. Rev., 58, pp. 621-681
• Custodio, A., Méndez, M., Provencio, M., Targeted therapies for advanced non-small-cell lung cancer: current status and future implications (2012) Cancer Treat. Rev., 38, pp. 36-53
• De Barros, A.L.B., Mota, L.G., Soares, D.C.F., Coelho, M.M.A., Oliveira, M.C., Cardoso, V.N., Tumor bombesin analog loaded long-circulating and pH-sensitive liposomes as tool for tumor identification (2011) Bioorg. Med. Chem. Lett., 21, pp. 7373-7375
• De Barros, A.L.B., Mota, L.G., Ferreira, C.A., Corrêa, N.C.R., De Goés, A.M., Oliveira, M.C., Cardoso, V.N., 99mTc-labeled bombesin analog for breast cancer identification (2013) J. Radioanal. Nucl. Chem., 295, pp. 2083-2090
• Devarakonda, S., Morgensztern, D., Govindan, R., Genomic alterations in lung adenocarcinoma (2015) Lancet Oncol., 16, pp. 342-351
• Diniz, S.O., Rezende, S.M., Serakides, R., Ferreira, R.L., Ribeiro, T.G., Martin-Comin, J., Cardoso, V.N., Scintigraphic imaging using technetium-99m-labeled ceftizoxime in an experimental model of acute osteomyelitis in rats (2008) Nucl. Med. Commun., 29, pp. 830-836
• Huang, G.S., Lopez-Barcons, L., Freeze, B.S., Smith, A.B., Goldberg, G.L., Horwitz, S.B., McDaid, H.M., Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice (2006) Clin. Cancer Res., 12, pp. 298-304
• Iwanski, G.B., Lee, D.H., En-gal, S., Doan, N.B., Castor, B., Vogt, M., Toh, M., Koeffler, H.P., Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer (2010) Br. J. Pharmacol., 160, pp. 998-1007
• Jang, S.H., Wientjes, M.G., Au, J.L., Kinetics of P-glycoprotein-mediated efflux of paclitaxel (2001) J. Pharmacol. Exp. Ther., 298, pp. 1236-1242
• Jarrar, B.M., Taib, N.T., Histological and histochemical alterations in the liver induced by lead chronic toxicity (2012) Saudi J. Biol. Sci., 19, pp. 203-210
• Kausar, H., Munagala, R., Bansal, S.S., Agil, F., Vadhanam, M.V., Gupta, R.C., Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets (2013) Cancer Lett., 332, pp. 35-45
• Kaushik, U., Aeri, V., Mir, S.R., Cucurbitacins – an insight into medicinal leads from nature (2015) Pharmacogn. Rev., 9, pp. 12-18
• Koh, P.K., Faivre-Finn, C., Blackhall, F.H., De Ruysscher, D., Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy (2012) Cancer Treat. Rev., 38, pp. 626-640
• Kubota, K., From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology (2001) Ann. Nucl. Med., 15, pp. 471-486
• Lang, K.L., Guimarães, T., Machado, V.R., Zimmermann, L., Silva, I.T., Teixeira, M.R., Durán, F.J., Schenkel, E.P., New cytotoxic cucurbutacins from Wilbrandia ebracteata Cogn (2011) Planta Med., 77, pp. 1648-1651
• Lang, K.L., Silva, I.T., Zimmermann, L., Machado, V.R., Teixeira, M.R., Lapuh, M.I., Galleti, M.A., Durán, F.J., Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives (2012) Bioorg. Med. Chem., 20, pp. 3016-3030
• Lang, K.L., Silva, I.T., Machado, V.R., Zimmermann, L., Caro, M.S.B., Simões, C.M.O., Schenkel, E.P., Melo, E.B., Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line (2014) J. Mol. Graph. Model., 48, pp. 70-79
• Lee, D.H., Iwanski, G.B., Thoennissen, N.H., Cucurbitacin: ancient compound shedding new light on cancer treatment (2010) Sci. World J., 10, pp. 413-418
• Li, F., Zhao, C., Wang, L., Molecular-targeted agents combination therapy for cancer: developments and potential (2014) Int. J. Cancer, 134, pp. 1257-1269
• Liu, T., Peng, H., Zhang, M., Deng, Y., Wu, Z., Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin (2010) Eur. J. Pharmacol., 641, pp. 15-22
• Mandaliya, H., Baghi, P., Prawira, A., George, M.K., A rare case of paclitaxel and/or trastuzumab induced acute hepatic necrosis (2015) Case Rep. Oncol. Med., 2015, pp. 1-2
• Marostica, L.L., Silva, I.T., Kratz, J.M., Persich, L., Geller, F.C., Lang, K.L., Caro, M.S., Simões, C.M.O., Synergistic antiproliferative effects of a new cucurbitacin B derivative and chemotherapy drugs on lung cancer cell line A549 (2015) Chem. Res. Toxicol., 28, pp. 1949-1960
• Marostica, L.L., De Barros, A.L.B., Silva, J.O., Lopes, S.C., Salgado, B.S., Chondrogiannis, S., Rubello, D., Oliveira, M.C., Feasibility study with 99m Tc-HYNIC-β-Ala-Bombesin(7-14) as an agent to early visualization of lung tumor cells in nude mice (2016) Nucl. Med. Commun., 37, pp. 372-376
• Milanovic, D., Braun, F., Weber, W., Grosu, A.L., Behe, M., Niedermann, G., The influence of the combined treatment with vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts (2012) BMC Cancer, 12, pp. 1-8
• Newman, D.J., Cragg, G.M., Natural products as sources of new drugs from 1981 to 2014 (2016) J. Nat. Prod., 79, pp. 629-661
• Ramalhete, C., Molnár, J., Mulhovo, S., Rosário, V.E., Ferreira, M.J., New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells (2009) Bioorg. Med. Chem., 17, pp. 6942-6951
• Ríos, I., Andújar, J.M., Escandell, R.M., Recio, M.C., Cucurbitacins as inducers of cell death and a rich source of potential cancer compounds (2012) Curr. Pharm. Design, 18, pp. 1663-1676
• Roland, C.L., Dineen, S.P., Lynn, K.D., Sullivan, L.A., Dellinger, M.T., Sadegh, L., Sullivan, J.P., Brekken, R.A., Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts (2009) Mol. Cancer Ther., 8, pp. 1761-1771
• Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017 (2017) CA Cancer J. Clin., 67, pp. 7-30
• Silva, I.T., Teixeira, M.R., Lang, K., Guimarães, T.R., Dudek, S.E., Durán, F.J., Ludwig, S., Simões, C.M.O., Proliferative inhibition and apoptotic mechanism on human non-small-cell lung cancer (A549 cells) of a novel cucurbitacin from Wilbrandia ebracteata Cogn (2013) Int. J. Cancer Res., 9, pp. 54-68
• Silva, I.T., Carvalho, A., Lang, K.L., Dudek, S.E., Durán, F.J., Caro, M.S.B., Rapp, U.R., Ludwig, S., In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B (2015) PLoS One, 10 (2), p. e0117794
• Sun, Y., Zhang, J., Zhou, J., Huang, Z., Hu, H., Qiao, M., Zhao, X., Chen, D., Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells (2015) Eur. J. Pharmacol., 768, pp. 28-40
• Wakimoto, N., Yin, D., O'Kelly, J., Haritunians, T., Karlan, B., Said, J., Xing, H., Koeffler, H.P., Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo (2008) Cancer Sci., 99, pp. 1793-1797
• Wall, M.E., Wani, M.C., Camptothecin and taxol: discovery to clinic – thirteenth Bruce F. Cain Memorial Award Lecture (1995) Cancer Res., 55, pp. 753-760
• Yamori, T., Sato, S., Chikasawa, H., Kadota, T., Anti-tumor efficacy of paclitaxel against human lung cancer xenografts (1997) J. Cancer Res. Ther., 88, pp. 1205-1210

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------